Education
About Us
Working with TipRanks
Follow Us
LIDDS AB (SE:LIDDS)
:LIDDS
Top Page
LIDDS AB
(Berlin:LIDDS)
Rating:37Underperform
Price Target:―
LIDDS AB (LIDDS) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr7.01M
Dividend YieldN/A
Average Volume (3M)250.08K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue GrowthN/A
EPS Growth94.98%
CountrySE
Employees1
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding136,463,330
10 Day Avg. Volume476,334
30 Day Avg. Volume250,078
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.27
Price to Sales (P/S)0.00
P/FCF Ratio-1.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
LIDDS AB Business Overview & Revenue Model
Company DescriptionLIDDS AB (LIDDS) is a Swedish pharmaceutical company that specializes in the development of innovative drug delivery systems for cancer treatments and other therapeutic areas. The company leverages its proprietary NanoZolid® technology to create injectable, controlled-release formulations that enhance the efficacy and safety profiles of active pharmaceutical ingredients. By focusing on improving drug delivery, LIDDS aims to address unmet medical needs and enhance patient outcomes across various clinical indications.
How the Company Makes MoneyLIDDS AB generates revenue through licensing agreements, collaborations, and partnerships with pharmaceutical companies interested in utilizing its NanoZolid® technology for their drug development projects. The company earns upfront payments, milestone payments, and royalties based on the commercial success of products developed using their technology. Additionally, LIDDS might engage in contract research and development services, offering its expertise in drug formulation and delivery. These strategic alliances and service offerings are crucial for the company's financial performance and growth in the competitive pharmaceutical industry.
LIDDS AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 23.00K | 0.00 | 1.89M | 3.55M | 345.00K | 0.00 | Gross Profit |
| -568.00K | -12.92M | -36.62M | -37.27M | -24.79M | -80.00K | EBIT |
| -5.41M | -40.67M | -36.62M | -37.27M | -32.33M | -23.82M | EBITDA |
| -3.67M | -39.67M | -36.12M | -36.81M | -32.20M | -31.30M | Net Income Common Stockholders |
| -4.30M | -40.21M | -37.10M | -37.27M | -32.34M | -23.83M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 10.95M | 13.51M | 5.26M | 34.00M | 36.07M | 7.56M | Total Assets |
| 13.66M | 17.66M | 25.92M | 55.58M | 54.20M | 158.09M | Total Debt |
| 0.00 | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | Net Debt |
| -10.95M | -13.51M | -1.26M | -34.00M | -36.07M | -7.56M | Total Liabilities |
| 3.48M | 3.76M | 10.57M | 7.07M | 11.40M | 5.96M | Stockholders Equity |
| 10.19M | 13.90M | 15.35M | 48.51M | 42.81M | 152.13M |
| Cash Flow | Free Cash Flow | ||||
| -5.53M | -26.50M | -36.40M | -45.04M | -31.17M | -36.01M | Operating Cash Flow |
| -5.43M | -26.22M | -35.59M | -42.64M | -27.42M | -17.09M | Investing Cash Flow |
| -95.00K | -282.00K | -810.00K | -2.40M | -3.75M | -18.92M | Financing Cash Flow |
| -280.00K | 34.76M | 7.66M | 42.97M | 59.64M | 17.44M |
LIDDS AB Technical Analysis
Neutral
0.04
Price Trends
0.05
Negative
0.10
Negative
0.11
Negative
Market Momentum
>-0.01
Negative
53.70
Neutral
40.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LIDDS, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 40.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:LIDDS.
LIDDS AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
38 Underperform | kr73.82M | ― | -105.78% | ― | 58.72% | 70.69% | |
37 Underperform | kr7.01M | ― | -107.11% | ― | ― | 94.98% | |
32 Underperform | kr11.90M | ― | -180.43% | ― | ― | 97.86% | |
30 Underperform | kr4.46M | ― | -186.04% | ― | ― | 57.91% |
* Healthcare Sector Average
Performance Comparison
SE:LIDDS
LIDDS AB
0.05
-0.10
-65.31%
SE:QUIA
QuiaPEG Pharmaceuticals Holding AB
0.01
-0.05
-83.33%
SE:SCOL
Scandion Oncology A/S
0.02
-0.40
-95.50%
SE:SPAGO
Spago Nanomedical AB
0.21
-0.13
-38.73%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.